key: cord-1005441-33u1cjzo
authors: Kananeh, Mohammed F.; Thomas, Tijo; Sharma, Kumud; Herpich, Franziska; Urtecho, Jacqueline; Kamran Athar, M.; Jabbour, Pascal; Shah, Syed Omar
title: Arterial and venous strokes in the setting of COVID-19
date: 2020-07-07
journal: J Clin Neurosci
DOI: 10.1016/j.jocn.2020.07.005
sha: 4d6df4c9a322695214291f05bf58e02abc4cd242
doc_id: 1005441
cord_uid: 33u1cjzo

BACKGROUND AND PURPOSE: Coronavirus disease 2019 (COVID -19) is a global pandemic that causes flu-like symptoms. There is a growing body of evidence suggesting that both the central and peripheral nervous systems can be affected by SARS-CoV-2, including stroke. We present three cases of arterial ischemic strokes and one venous infarction from a cerebral venous sinus thrombosis in the setting of COVID-19 infection who otherwise had low risk factors for stroke. METHODS: We retrospectively reviewed patients presenting to a large tertiary care academic US hospital with stroke and who tested positive for COVID-19. Medical records were reviewed for demographics, imaging results and lab findings. RESULTS: There were 3 cases of arterial ischemic strokes and 1 case of venous stroke: 3 males and 1 female. The mean age was 55 (48-70) years. All arterial strokes presented with large vessel occlusions and had mechanical thrombectomy performed. Two cases presented with stroke despite being on full anticoagulation. CONCLUSIONS: It is important to recognize the neurological manifestations of COVID-19, especially ischemic stroke, either arterial or venous in nature. Hypercoagulability and the cytokine surge are perhaps the cause of ischemic stroke in these patients. Further studies are needed to understand the role of anticoagulation in these patients.

Coronavirus disease 2019 (COVID -19) is a global pandemic that causes flu-like symptoms. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system leading to acute respiratory distress syndrome (ARDS), intubation and mechanical ventilation. Multi-organ failure and hypercoagulable states have also been observed in COVID-19 patients [1] [2] [3] [4] . There is a growing body of evidence suggesting that both the central and peripheral nervous systems can be affected by SARS-CoV-2 [5, 6] . We present three cases of arterial ischemic strokes and one venous infarction from a cerebral venous sinus thrombosis in the setting of COVID-19 infection who otherwise had low risk factors for stroke.

We retrospectively reviewed patients presenting to a large tertiary care academic US hospital with stroke and who tested positive for COVID-19. SARS-CoV-2 infection was confirmed in all patients by detection of viral nucleic acid in a nasopharyngeal swab, using the reversetranscriptase-polymerase-chain-reaction (RT-PCR) assay. Medical records were reviewed for demographics, imaging results and lab findings.

A 51-year-old male with history of hypertension (HTN), coronary artery disease (CAD), and hyperlipidemia (HLD) was admitted to an outside hospital (OSH) with progressive shortness of breath and cough for four days. He was confirmed COVID-19 positive and required 6 liters nasal cannula oxygen. In accordance to the OSH COVID-19 treatment policy, the patient was started on therapeutic dose enoxaparin (1 mg/kg) upon admission. On hospital day 2, he was found to be hemiplegic on the left side with an NIHSS of 20. The patient did not receive IV tPA given he was on therapeutic enoxaparin. CTA head and neck demonstrated a tandem occlusion: acute thrombus in the right internal carotid artery (ICA) from its origin and an M1 occlusion. He was transferred to our hospital for endovascular intervention. Shortly after transfer, the patient developed worsening hypoxia and required mechanical intubation while in the angiography suite.

He underwent mechanical thrombectomy (TICI 0 to 2B) with five stent placements to the right ICA. He was loaded with aspirin and clopidogrel and therapeutic enoxaparin was discontinued.

Post stroke day 1, a repeat CT head in the neurocritical care unit (NICU) showed a large right middle cerebral artery (MCA) territory stroke ( Figure 1 ). Table 1 

A 70-year-old female with no significant past medial history was admitted to an OSH for shortness of breath (SOB), fever, hypoxia and new onset atrial fibrillation (A-Fib). She was confirmed to be COVID-19 positive and started on hydroxychloroquine and azithromycin. Her hypoxia was treated with non-rebreather mask. Per the OSH policy, she was initiated on therapeutic enoxaparin (1 mg/kg) for the new onset A-Fib. On hospital day 3, she was found to be altered with acute left hemiparesis and facial droop with an NIHSS of 28. The patient did not receive IV tPA due to therapeutic enoxaparin. CTA head and neck demonstrated an acute right M2 occlusion. She was transferred to our hospital and underwent a successful thrombectomy (TICI 0 to 2A). While in the interventional suite, she became increasingly hypoxic and required intubation and mechanical ventilation. Table 1 In the NICU, the patient was positive for COVID-19 despite not having any recent symptoms. MRI brain showed a large acute infarct in the left MCA territory, with mass effect and mild petechial hemorrhage (Figure 4 ). Aspirin and statin therapy have been initiated for secondary stroke prevention along with subcutaneous heparin for DVT prophylaxis. His labs are pertinent for significantly elevated D-dimer (Table 1) . His NIHSS improved to 10 and currently he is in the stroke unit awaiting discharge to a rehab facility.

Coronaviridae is a family of RNA viruses that were isolated in the 1960s [5, 7] . The first cases of SARS-CoV-2 were discovered in Wuhan, China in December 2019 [8] . Since then, the infection has become a pandemic affecting over 2 million individuals with a mortality close to 7% globally. Most commonly, patients manifest an upper respiratory tract infection or flu-like symptoms. In one review, up to 71% of patients developing ARDS require intubation and mechanical ventilation [1] . These patients can also have acute kidney injury (AKI), elevated liver enzymes, and cardiac injury [2] . A majority of patients manifest coagulopathy and increased inflammation with elevated CRP (75-93%), LDH (27-92%), ESR (85%) and D-dimer (36-43%) [9] . Neurologic manifestations are more common than expected in COVID-19 patients. In a recent review in China, 36.4% of COVID-19 patients had neurologic manifestations, ranging from skeletal muscles injury to acute cerebrovascular disease. The prevalence of cerebrovascular disease was low in this review with only 1-5% of patients developing symptoms of cerebrovascular disease [6] . A multi-center prospective study in intensive care units (ICUs) in France found that close to 3% of COVID-19 patients develop ischemic strokes [3] . Patients with severe symptoms are more likely than patients with mild to moderate symptoms to have neurological manifestations [6] .

In our case series, we present four cases of cerebrovascular disease who had concurrent COVID-19 infection. Our patients displayed evidence of hypercoagulability and significantly increased inflammatory markers. All four cases were positive for anticardiolipin antibodies. The first patient was positive for anti-B2-glycoprotein I IgA and IgG antibodies. A recent publication showed an association with the development of ischemic infarcts and the presence of these antibodies [10] . All patients had elevated D-Dimers and other inflammatory markers.

The mechanism on how the SARS-CoV-2 virus causes ischemic strokes is unclear. Several theories have been proposed. The elevated D-dimer in COVID-19 patients can be associated with the development of ischemic stroke. Elevated D-dimer increases blood coagulation, thrombin formation, and intravascular fibrin. In addition, elevated D-dimer concentrations have been reported in cerebral venous sinus thrombosis, acute pulmonary embolism, spontaneous intracerebral hemorrhage [11] . The increased hypercoagulability can directly lead to clot formation in the large intracranial vessels and increased risk for ischemic stroke. In addition, the SARS-CoV-2 virus has been associated with a cytokine surge that is linked with the development of acute cerebrobasilar disease [12] . In our patients, the LDL and HBA1C were at normal levels. Their bedside echocardiograms were unrevealing. It is possible that the hypercoagulability and inflammatory surge that accompanies COVID-19 infection can lead to ischemic infarcts through clot formation in large intracranial vessels. Moreover, the accompanying hypoxemia can lead to ischemic stroke by increasing intracellular acidosis and free radicals. This process can eventually lead to cell damage and apoptosis [13] . Damage to the central nervous system can also come from direct invasion of the virus to brain cells. Brain autopsy in deceased COVID-19 patients detected the nucleic acid of the virus in their cerebrospinal fluid and brain tissue [14] . Perhaps the invasion is a result of ACE2 receptors in cerebral blood vessels similar to the invasion that occurs in lung tissue, but further research is required to validate this [15] . Another animal model showed that the olfactory nerve could be the point of entry of the virus to the brain [15] .

Tang et al. suggested that anticoagulation therapy with low molecular weighted heparin (LMWH) is associated with better prognosis in severely affected COVID-19 patients with elevated D-dimer [4] . It is important to note that the first two cases developed strokes while on full dose anticoagulation. This raises an important question on the best way to anticoagulate COVID-19 patients to prevent future strokes. Further research is warranted to help answer this question.

The SARS-CoV-2 virus has caused a pandemic that has overwhelmed healthcare providers around the world. Multiorgan failure has been described in patients with the COVID-19 infection including the central and peripheral nervous systems. It is important to recognize the neurological manifestations of COVID-19, especially ischemic stroke, either arterial or venous in nature. Hypercoagulability and the cytokine surge are perhaps the cause of ischemic stroke in these patients. Early anticoagulation may help prevent ischemic stroke in patients with elevated D-Dimer. It is unclear which agent and dose is required to help prevent the occurrence of ischemic strokes in patients who are severely ill. Further studies are needed to understand the role of anticoagulation in these patients. 

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. Epub ahead of print 4

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Neurologic Manifestations of Severe Respiratory Viral Contagions. Crit Care Explor. Epub ahead of print

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures

Pandemic potential of 2019-nCoV

Laboratory abnormalities in patients with COVID-2019 infection

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke

COVID-19: consider cytokine storm syndromes and immunosuppression

Mitochondrial function in hypoxic ischemic injury and influence of aging

Middle East Respiratory Syndrome

Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients

19 is a global pandemic that has overwhelmed health care systems around the world

CoV-2 can affect both the central and peripheral nervous systems.  Arterial and venous ischemic strokes can occur in COVID-19 patients

 Strokes in COVID-19 patients can occur while on therapeutic dose of anticoagulation.  Elevated D-dimer and inflammatory markers are a possible cause of strokes in COVID-19 patients